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Abstract: The long-standing dearth of knowledge
surrounding Plasmodium vivax, the most widely distrib-
uted of the malaria species, merits urgent attention. A
growing awareness of the true burden of this parasite and
its potential to cause severe disease, and the identification
of increasing parasite resistance in many areas of the
world to chloroquine, the mainstay of vivax treatment,
underscores the need to identify new and effective
treatment strategies. Artemisinin-based combination ther-
apies (ACTs) have been widely adopted as first-line
treatment for P. falciparum malaria and would offer
logistic benefits in areas of co-endemicity. However, while
ACTs show high and similar efficacy against the blood
stages of P. vivax, neither ACTs nor chloroquine are active
against vivax hypnozoites and must be complemented
with a full course of primaquine to eradicate dormant
vivax hypnozoites and prevent relapses. Artemether-
lumefantrine (AL), the most commonly deployed ACT,
has shown rapid clearance of P. vivax parasitemia and
fever. The relatively short half-life of lumefantrine would
appear beneficial in terms of reducing risk of resistance
when compared to other ACTs. However, it has a shorter
capability to suppress vivax relapses or prevent de novo
infections, which generally translates into comparatively
lower in vivo short-term measures of efficacy (e.g., day 28
or day 42 uncorrected cure rates). Assuming that the
different artemisinin derivatives have equivalent efficacy
against vivax, differences between AL and other ACTs may
be restricted to the duration of plasma therapeutic levels
of the partner drug, a variable of limited clinical relevance,
particularly in regions with low vivax transmission rates or
in cases where primaquine is added to the regimen to
prevent relapses. More rigorous assessment of the use of
ACTs in general, and AL in particular, for the treatment of
P. vivax infections, either alone or in combination with
primaquine, is merited. In the meantime, AL treatment of
vivax malaria may be a pragmatic choice for areas with
chloroquine-resistant P. vivax, and in co-endemic areas
where AL is already used routinely against P. falciparum
and parasitological differentiation is not routinely per-
formed or only clinical diagnosis is used.
Introduction
Plasmodium vivax infection persists as a major global health
problem. It is more widely distributed than P. falciparum [1], with
over 2.5 billion people living at risk and an estimated 80 to 300
million clinical cases each year [2,3]. It is common in Asia,
Oceania, Central and South America and the Middle East [1,3],
but its burden is also increasingly recognized in East Africa [4–6]
and, more recently, in other African regions with reports from
western African countries including Democratic Republic of the
Congo, Co ˆte D’Ivoire, and Equatorial Guinea [1,7]. The belief
that the virtual absence of the red blood cell Duffy-positive
phenotype among black Africans protects these populations
against P. vivax infections [8] (the Duffy protein is thought to
be necessary for the parasite’s invasion of reticulocytes) is
under reconsideration [9], and it is now hypothesized that P.
vivax may invade young red blood cells using alternative
mechanisms [10].
Traditionally, P. vivax has been regarded as a benign infection.
This idea, however, has recently been challenged [2,11–14], and
the literature reflects increasing reports of vivax-attributable severe
or even life-threatening illness [15–17]. Episodes of P. vivax
infection should thus be regarded as potentially lethal and should
prompt urgent treatment with effective antimalarial medication.
In the majority of settings, P. vivax coexists with P. falciparum
[18–20]. Although the examination of thin blood slides using
optical microscopy has traditionally been used for species
differentiation, accurate species diagnosis is difficult, and ultimate-
ly may require highly specific PCR methods, not applicable in the
daily clinical routine. The sensitivity of rapid diagnostic tests is
limited when trying to differentiate between these two species,
especially at low parasitemias, common in P. vivax infections
[21,22]. In resource-challenged regions, empiric treatment based
on clinical suspicion is widely accepted and implemented,
although no longer recommended by the World Health Organi-
zation (WHO) [20].
Programmatically, the use of a single first-line therapy
effective against both P. vivax and P. falciparum would be ideal
in view of the frequent co-endemicity of the two species and the
increasing resistance of parasites to chloroquine. The wide-
spread adoption of artemisinin-based combination therapies
(ACTs) as highly effective first-line therapy for P. falciparum has
prompted a closer examination of their role in the management
of P. vivax malaria. This article considers the available evidence
relating to the potential role of artemether-lumefantrine (AL),
the most widely used ACT worldwide, in the management of
vivax malaria.
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An electronic search of articles published on or before 31
January 2011 was performed in EMBASE, Medline, PubMed, and
BIOSIS Previews. Search terms were ‘‘artemether-lumefantrine,’’
‘‘artemether,’’ ‘‘artemisinin,’’ ‘‘Plasmodium vivax,’’ and ‘‘vivax,’’
with no time or language restrictions. Search results were
examined for clinical studies of AL in the treatment of
uncomplicated P. vivax malaria, including subpopulation analyses.
The limited number of relevant, well-designed trials meant that no
meaningful meta-analysis could be performed.
P. vivax Life Cycle and Implications for the
Evaluation of Efficacy of Antimalarials
In contrast to P. falciparum, P. vivax forms hypnozoites that can
remain dormant in the parenchymal cells of the host liver
following an acute infection. After an interval of time, which varies
in duration depending on the geographical area [3], the
hypnozoites can mature into hepatic schizonts that rupture to
release merozoites capable of infecting erythrocytes and inducing a
spontaneous relapse (Figure 1). Clinically, relapses present as a
new malaria episode, indistinguishable from a new infection.
Thus, in P. vivax infections, the eradication of blood schizonts is
not sufficient to control the disease, and an effective treatment
requires killing the hypnozoites (‘‘radical cure’’) to prevent future
relapses. Chloroquine, an inexpensive and effective treatment for
vivax malaria in most areas of the world [23] has been the
mainstay first-line therapy for this species for the past seven
decades. It is still WHO’s recommended drug for vivax, but needs
to be combined with primaquine, currently the only approved
drug capable of achieving radical cure of hypnozoites [18,24,25].
WHO guidelines state that primaquine needs to be administered
daily for 14 d to achieve this purpose [20], although the efficacy of
shorter (7 d) courses is being investigated. Chloroquine achieves
parasitological cure at day 28 in more than 90% of chloroquine-
sensitive P. vivax infections [26], but in many areas of the world,
significant levels of resistance to this drug in P. vivax have been
documented [19,27,28], notably in Indonesia (,50% probability
of therapeutic success) [19] and to a lesser extent in India [29],
Myanmar [30], Turkey [31], the Brazilian Amazon [32], and
Colombia [33]. Worryingly, there is also growing evidence of
clinical resistance of vivax to chloroquine in Africa [34–36].
Emergence of resistance to chloroquine, particularly in view of the
potentially serious consequences of vivax infection, adds a further
urgency to providing effective therapy.
The possibility of relapse brings about uncertainty when
assessing the efficacy of antimalarial drugs that have an effect on
asexual stages of the life cycle but not on the dormant liver forms.
Thus, patients correctly treated with an antimalarial with no
antihypnozoite activity may present with recurrent post-treatment
parasitemia that can derive from one of three sources: (1)
reappearing parasites as a result of the incomplete clearance of
the original infection (recrudescence), often the consequence of
ineffective or incomplete treatment, (2) generation of de novo
parasitemia from the liver reservoirs (relapse), or (3) parasites
ensuing from a new and independent infection (new infection)
(Figure 2). Parasites in recrudescent or relapsing infections may be
genetically identical to the original infection and thus impossible to
differentiate with current technology. Some reports state that over
Figure 1. P. vivax life cycle and sites of action for different antimalarials.
doi:10.1371/journal.pntd.0001325.g001
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preceding documented infection, but this may be explained by
older heterologous hypnozoites becoming reactivated [37]. A new
infection arising from the bite of an infected vector, however, may
differ from the original infecting parasite such that they can be
distinguished from one another by PCR molecular techniques. A
pragmatic solution to this investigative hurdle has been adopted
whereby any new parasitemia appearing before day 16 is by
convention directly classified as recrudescence (i.e., treatment
failure) because of the unlikelihood of the infection being a relapse
within such a short space of time, and because this is the minimum
incubation period for a new infection to appear in peripheral
blood. Reappearance of parasites after day 16 cannot be assumed
to be recrudescence [20].
ACTs in Vivax Malaria
ACTs are highly effective against uncomplicated P. falciparum
malaria and are now recommended as first-line therapy [20],
having been adopted in most countries where P. falciparum is
endemic. Most ACTs show high and similar efficacy against the
blood stages of P. vivax [38], but none is active against the hepatic
P. vivax hypnozoites responsible for relapse [39]. Therefore, in
order to achieve radical cure, similar to chloroquine treatment,
ACT treatment must be complemented with a full course (14 d) of
primaquine.
Where both P. vivax and P. falciparum species are prevalent and
ACTs have been adopted as first-line therapy for P. falciparum, use
of a unified first-line therapy based on ACTs would simplify
treatment procurement, distribution, and management, offering
interesting logistical benefits. ACT therapy for both types of
infections would also avoid the problem of P. falciparum being
mistakenly diagnosed as P. vivax and inadequately treated with
chloroquine in the many regions where diagnosis is based on
clinical symptoms alone [18]. In areas of chloroquine-resistant P.
vivax, and where ACTs have already been adopted for the
treatment of P. falciparum malaria, ACTs could also be used for the
treatment of vivax, provided they are complemented with the
standard primaquine course [20]. Indeed, at least four countries
have now adopted a unified first-line therapy based on ACTs: the
Solomon Islands, Vanuatu, and Papua New Guinea deploy AL,
while Indonesia deploys dihydroartemisinin-piperaquine (DHA-
PQP) in Papua [18].
Rationale for Use of AL
A large evidence base is now available to demonstrate the
efficacy of AL in the treatment of uncomplicated malaria in a
range of patient types and locations worldwide, but particularly for
P. falciparum infections. This includes the most extensive data for
any ACT in children and pregnant women [40–44], the two
populations most vulnerable to malaria. AL also offers the most
Figure 2. Possible sources of residual blood parasitemia after initial treatment and possible genetic similarity or dissimiliarity.
doi:10.1371/journal.pntd.0001325.g002
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used ACT for falciparum malaria worldwide, with over 400
million treatments having already been distributed. Moreover, it is
the only ACT with a formulation specifically tailored to use in
children that is recommended by WHO. Last, but not least,
resistance to lumefantrine in field isolates has not yet been
convincingly demonstrated, an important advantage attributed to
the relatively short half-life of lumefantrine [46] and the fact that,
in contrast to most other ACT partner drugs, lumefantrine has
never been used as monotherapy.
Impact of the Partner Drug’s Half-Life on Efficacy
of ACTs in Vivax Infections
ACTs in which the partner drug has a long half-life are
theoretically considered preferable in vivax infections [20], since
this would be expected to extend the period of prophylaxis against
either new infections or latent ones ensuing from the dormant
hypnozoites in the liver. In an analysis of 10,549 patients treated
for falciparum malaria on the Thailand–Myanmar border during
1991–2005, 11% (n=1,164) of whom had mixed falciparum/
vivax infection at screening, the rate of P. vivax infection by day 63
was 12.0% (n=1,269) for vivax monoinfection and 0.8% (n=86)
for mixed infections [47]. ACTs that included partner drugs with
shorter half-lives increased the risk of vivax infection recurrence by
day 63 after treatment for P. falciparum malaria: the more rapidly
eliminated AL and artesunate-atovaquone-proguanil combina-
tions were associated with a 3.6-fold and 4.2-fold higher adjusted
hazard ratio, respectively, for P. vivax infection than artesunate-
mefloquine (p,0.001). No difference was observed for AL versus
DHA-PQP or artemether-mefloquine combinations.
Lumefantrine, the partner drug in AL, has a relatively short
half-life (3–6 d [48]) compared to mefloquine 12–15 d [49],
amodiaquine 1–3 wk [50], or sulfadoxine 6–11 d [51]. Pyrimeth-
amine and lumefantrine share a similar half-life (2–3 d [52]).
Other than for chloroquine (up to 2 mo [50]) and piperaquine
(23–28 d [53]), the differences in half-lives are, however, relatively
small, and the advantage of a longer half-life is potentially
counterbalanced by an increased risk for selection of resistant
parasites, especially in areas of intense transmission [46,54].
Antimalarial drugs have the potential to suppress the relapse of
hepatic dormant stages as long as plasmatic levels remain above
the therapeutic threshold. However, when drug concentrations
decrease or even disappear, so does the capacity of the drug to
inhibit relapses. Thus, although artemether individually shows
similar efficacy rates to artesunate [38], standard measures of
efficacy (e.g., 28-d parasitemia cure rate) are generally lower with
AL than with other ACTs because lumefantrine is cleared from
the blood rather quickly, leading to potentially earlier relapses.
However, relapse of vivax infection is only delayed, and not
prevented, by longer-acting partner drugs since an extended half-
life does not influence the viability of hypnozoites in the liver and
relapse can still occur once the drug is cleared. Over longer follow-
up periods, the incidence of relapse would be expected to converge
regardless of which ACT was employed. It has been proposed that
an accurate comparison of relapse rates in vivax malaria requires
at least 2 mo of follow-up [55], which is only rarely undertaken in
clinical studies.
Efficacy of AL in P. vivax Infection
Clinical investigations into the efficacy of antimalarial agents
have been far less extensive for P. vivax than for P. falciparum,
confirming its relative neglect [13]. Indeed, only a handful of
clinical trials of AL in the treatment of P. vivax monoinfection have
been published [34,38,56,57]. In most studies [58–68], data on AL
efficacy have been derived from subpopulation analyses within
larger studies of both P. falciparum and P. vivax infections.
Clinical Response
AL is highly effective against the blood stages of P. vivax
infection, consistent with results from trials of AL in falciparum
malaria [42,69,70]. The most informative indicator of efficacy is
parasitological cure, since the clinical failure rate excludes
asymptomatic parasitological failures that are detected only at
routine follow-up visits. Nevertheless, it is important to note that
fever resolution is rapid following AL therapy [38,56,57,59].
Parasite clearance [38,56,57] is achieved rapidly in vivax-
infected patients. This is not unexpected, since in vitro data have
shown similar efficacy for artemether versus asexual forms of P.
falciparum and P. vivax [44]. Reports from subpopulations with
vivax monoinfection [38,56,57,59] or mixed vivax and falciparum
infection [57,59,60,65,67] have shown rapid clearance of both
species’ parasitemia in all patients following AL treatment
(Table 1). In a cohort of 33 children with vivax monoinfection,
mean time to parasite clearance following AL treatment was
33.6 h, with all patients being fully cleared of their parasites by day
7 [59].
Comparison with Chloroquine and Other Antimalarials
One randomized trial compared the therapeutic response
against vivax monoinfection of different orally administered
antimalarials in a Thai population of 207 patients [38]. The rate
of parasite clearance was markedly faster with artemether and
artesunate than with the other non-ACT antimalarials (Table 1).
When the baseline parasite count was taken into consideration, by
calculating the ratio of the parasite count before treatment to the
count at 48 h (‘‘parasite reduction rate’’), clearance rates were
higher with artemether (median 1,720), with values 14-fold greater
than for the other treatments, with the exception of artesunate
(median 1,507). Correspondingly, the mean fever clearance time
(defined as the time for body temperature to fall below 37.5uC and
remain below this value for .48 h) was fastest in patients treated
with artemether or artesunate compared to other antimalarials in
this study [38], consistent with results from a randomized trial in
Indonesia [56] (Table 1). Other authors have reported a similar
time to resolution of fever with AL or chloroquine-primaquine
[56].
P. vivax Relapse
Comparison with Chloroquine
As discussed above, the relatively short lumefantrine half-life
often implies a lower day 28 uncorrected parasitological cure rate
with AL than with antimalarials that have a longer half-life,
including chloroquine and chloroquine-primaquine [34,71]. In a
recent study of AL versus chloroquine monotherapy in 133
patients with vivax malaria in Ethiopia, the uncorrected day 28
failure rate for AL was 19.0% (95% CI 2.9%–18.9%), compared
to 7.5% for chloroquine (95% CI 11%–31.6%) [34] (Table 2).
This difference would be expected in view of the relatively long
half-life of chloroquine [50]. Resistance to chloroquine and
subtherapeutic drug levels could explain the five recrudescences
observed in the chloroquine group, but amongst the 19 cases of
treatment failure in AL-treated patients [34], it is not possible to
differentiate between relapse, recrudescence, or reinfection. One
could speculate that most new parasitemias probably derived from
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failure occurred during days 21–28; new infections were also
possible, but unlikely because of the low transmission intensity in
the area. The authors also suggested that since the evening doses
of AL were unsupervised, full compliance could not be confirmed,
although good compliance with the AL dosing regimen has
generally been observed [72,73].
The longest follow-up data comparing AL (without primaquine)
to chloroquine-primaquine derive from a study in 132 Chinese
patients with vivax malaria [56]. While initial parasite clearance
was significantly faster with AL than with chloroquine-primaquine
(33.5 h versus 44.9 h, p,0.01), cumulative relapse rates 9 mo after
the initial infection were significantly higher in the two AL dosing
groups (84.9% and 78.8% versus 22.9% in patients treated with
chloroquine-primaquine, p,0.01). This is as expected, since
radical cure requires concomitant administration of primaquine.
Only one trial has evaluated the efficacy of AL versus
chloroquine when both are administered in combination with
primaquine in the treatment of P. vivax malaria [57]. In this study,
98 non-G6PD-deficient adult patients with vivax malaria in
Thailand were randomized to AL or chloroquine, both adminis-
tered with primaquine. Mean time to parasite clearance was
shorter in the AL-primaquine group (41.6 h versus 55.8 h,
p,0.01), and all but one of the 47 AL patients achieved
parasitological cure by day 28 (97.4%). For the remaining patient,
in whom parasitemia was detected at day 26, de novo reinfection
was excluded since the patient had remained in hospital; relapse
was considered the most likely cause. All patients receiving
chloroquine-primaquine achieved parasitological cure. The au-
thors concluded that AL with primaquine was as effective as
chloroquine with primaquine for the treatment of vivax malaria
[57]. It is clear that more studies are needed to specifically
investigate the combined efficacy and potential toxicity of AL and
primaquine. To date, however, there has been no indication of
safety or toxicity concerns in patients treated for vivax infection
with AL alone [34,38,57,62] or in the single study of AL in
combination with primaquine [57]. The absence of an effect of
artemether on the metabolism of primaquine [74] and the absence
of an inhibitory or induction effect of lumefantrine on the CYP
enzymes involved in the metabolism of primaquine (i.e., CYP1A2
and CYP3A4 [75]) suggest that a drug–drug interaction between
the two drugs is unlikely.
Comparison with Other ACTs
Studies comparing the efficacy of artemisinin monotherapies to
treat vivax malaria are scarce and no longer considered ethical. In
Table 1. Parasite and fever clearance times in patients treated with artemether or AL for P. vivax.
Study
Population
(Location) Treatment
Sample
Size Parasite Clearance Time Fever Clearance Time
Mean Time
(Hours) p-Value
Mean Time
(Hours) p-Value
Karunajeewa
et al. [59]
Children 0.5–5 y
(Papua New Guinea)
AL 33 33.6 ,0.001 50.4 0.94
Chloroquine-sulfadoxine-
pyrimethamine
51 74.4 55.2
Artesunate-sulfadoxine-
pyrimethamine
39 26.4 50.4
DHA-PQP 38 28.8 45.6
Krudsood
et al. [57]
Adults ($15 y)
(Indonesia)
AL-primaquine 47 41.6 (mean;
range 14–71)
,0.001 21.8 (mean;
range 4–70)
0.12
Chloroquine- primaquine 51 55.8 (mean;
range 23–106)
25.3 (mean;
range 4–90)
Li et al. [56] Age not specified
(China)
AL
a 36 33.5 ,0.01 22.3 (mean) n.s.
Chloroquine- primaquine 55 44.9 25.0 (mean)
Pukrittayakamee
et al. [38]
Adults ($15 y)
(Thailand)
b
Artemether
c 20 50 n.s. for artemether versus
chloroquine-primaquine;
p=0.02 for artemether
versus artesunate
14 ,0.001 for
artemether or
artesunate versuss
other treatments
Artesunate 20 38 17
Chloroquine-primaquine 30 64 30
Chloroquine 30 65 31
Primaquine 30 83 28
Quinine 22 98 31
Mefloquine 20 76 21
Halofantrine 23 85 21
Pyrimethamine-sulfadoxine 12 114 58
aStandard 3-d AL regimen.
bData on parasite clearance time available for 195/207 patients.
c2.7 mg/kg on day 1, 1.3 mg/kg/d for a further 4 d.
n.s., not significant.
doi:10.1371/journal.pntd.0001325.t001
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population of Thai patients. P. vivax relapse rates were similar for
artemether (9/17 [52.9%]) and artesunate (12/19 [63.2%])
[38,71]. Parasite clearance time and fever clearance time were
shortest among patients receiving artemether or artesunate
compared to other non-artemisinin-based antimalarials, with no
statistically significant differences between the two artemisinin
derivatives [38].
Two studies have compared parasitological cure rates in vivax
infection using AL or DHA-PQP: both studies showed a higher
cure rate for the latter [59,62] (Table 2). A study of 161 infants and
children with P. vivax malaria in Papua New Guinea reported a
significantly higher day 28 parasitological failure rate with AL,
artesunate-sulfadoxine-pyrimethamine, and chloroquine-sulfadox-
ine-pyrimethamine compared to DHA-PQP [59]. Ratcliff et al.
[62] also observed a higher failure rate with AL versus DHA-PQP,
this time in an Indonesian population [62].
Prevention of De Novo Vivax Infection
Different studies have assessed the appearance of de novo vivax
infections in patients treated with AL for falciparum [58,61,64,66]
(Table 3). van den Broek et al. [66] observed a significantly higher
number of new P. vivax infections at 6 wk in Bangladeshi patients
treated with AL (25/121 [20.7%]) for falciparum malaria than in
those treated with artesunate-mefloquine (6/121 [5.0%]) or
chloroquine-sulfadoxine-pyrimethamine (4/122 [3.3%]), with all
vivax infections occurring late in follow-up (21–42 d) [66].
Similarly, in a cohort of 330 patients treated for uncomplicated
falciparum malaria in Laos and followed for 42 d, five cases of
vivax appeared in AL-treated individuals (5/110 [4.5%]) at a
median of 28 d, compared to none in the 110 patients randomized
to artesunate-mefloquine or chloroquine (not significant) [61].
Smithuis et al. [64], analyzing data from a population of 679
Myanmarese patients with P. falciparum monoinfection, observed
that 194 (28.6%) had one or more episodes of P. vivax infection
during the 63-d follow-up [64]. The highest rate of new vivax
infections at day 63 was seen in the AL cohort, but since only
,40% of AL-treated patients provided data at day 63, the results
should be interpreted with caution (Table 3). Early appearance of
vivax infections, in patients with either only falciparum infection
or mixed falciparum/vivax infection at baseline, was similarly low
until day 14, consistent with reports that all patients with vivax
malaria achieve clinical recovery [38] and parasite clearance by
day 7 [59] following AL treatment. In this study, the median time
to P. vivax recurrence was 35, 49, 42, 49, and 56 d, respectively, in
the AL, artesunate-amodiaquine fixed dose, artesunate-mefloquine
loose tablet, artesunate-mefloquine fixed dose, and DHA-PQP
groups, respectively (p=0.0001) [64]. Other authors have reported
mixed results when comparing new P. vivax infections in patients in
whom AL or artesunate-mefloquine was administered for
treatment of falciparum malaria at baseline [58,61]. A recent
meta-analysis confirms the superiority of both DHA-PQP and
artesunate-mefloquine to AL in reducing the incidence (reappear-
ance or new infection) of P. vivax over 42 d [39], but in view of the
Table 2. Parasitological failure in patients treated with AL for P. vivax.
Study Population (Location) Follow-Up Treatment
Sample
Size
Parasitological
Failure p-Value
Yohannes et al. [34] Adults and children $1 y (Ethiopia) 28 d AL 75 19% 0.015
Chloroquine 87 7.5%
Li et al. [56] Age not specified (China) 9 mo AL 36 84.9%
a ,0.01
Chloroquine- primaquine 55 22.9%
a
Pukrittayakamee et al. [71] Adults ($15 y) (Thailand) 28 d Artemether
b 20 52.9%
c —
Artesunate 20 63.2%
c
Chloroquine-primaquine 26 0
c
Chloroquine 49 0
c
Primaquine 30 11.5%
c
Quinine 22 64.7%
c
Mefloquine 16 0
c
Halofantrine 23 52.9%
c
Karunajeewa et al. [59] Children 0.5–5 y (Papua New
Guinea)
28 d
d AL 33 45.5% 0.001 for AL
versus DHA-PQP
Chloroquine-sulfadoxine-
pyrimethamine
51 41.2%
Artesunate-sulfadoxine-
pyrimethamine
39 46.2%
DHA-PQP 38 15.8%
Ratcliff et al. [62] Adults and children $10 kg
(Indonesia)
42 d AL 141 57% ,0.001
DHA-PQP 147 14%
aRelapse rate.
b2.7 mg/kg on day 1, 1.3 mg/kg/d for a further 4 d.
cSubsequent appearance of malaria.
dParasitological failure at 42 d: AL 54.5%, chloroquine-sulfadoxine-pyrimethamine 65.3%, artesunate-sulfadoxine-pyrimethamine 48.7%, DHA-PQP2 7 . 8 %( p=0.001
versus AL).
doi:10.1371/journal.pntd.0001325.t002
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may not be sustained in the long term. In areas of intense vivax
transmission that have only limited use of primaquine, however,
prevention of de novo vivax infections may be achieved more
effectively by ACTs in which there is an extended partner half-life.
Gametocidal Effect
Unlike in P. falciparum, where gametocytogenesis is delayed until
the appearance of clinical symptoms, P. vivax generates gameto-
cytes at an early stage of the infection, often preceding any
symptomatology. This explains the high rate of gametocyte
carriage (,60%) often present in vivax infections [62,71,76]. As
a result, vivax can be transmitted to other individuals before
patients have started any treatment, a circumstance which is
further aggravated by the fact that P. vivax achieves effective
transmission at low blood densities.
In P. falciparum infections, most antimalarial agents other than
ACTs have little or no effect on gametocyte development [77–79].
However, all antimalarial agents are considered effective against
both the asexual and sexual stages of P. vivax malaria [71]. Few
prospective studies, however, have compared the gametocytocidal
activity of different therapies against vivax, and no adequate in
vitro models exist. The limited data available, however, suggest
that artemisinin derivatives such as AL clear P. vivax gametocytes
rapidly [62,71], but the overall effect on gametocyte carriage is less
marked than in falciparum infections because of the proportionally
higher individual burden of gametocytes that the drug has to deal
with. One prospective study of 349 adults with P. vivax malaria in
Thailand, undertaken outside a malaria transmission area,
compared eight different antimalarial agents [71]. In this cohort,
77 patients (22%) had vivax gametocytemia on admission, and a
further 144 (41%) developed gametocytemia after treatment. The
median time to gametocyte clearance was shortest with AL (8 h),
artesunate (4 h), and chloroquine-primaquine (2 h), with a
markedly longer clearance time in patients receiving mefloquine
(24 h), primaquine (24 h), or quinine (20 h).
In falciparum malaria, two studies have indicated that AL exerts
a more potent gametocytocidal effect than DHA-PQP [80,81],
while two have suggested the converse [82,83]; overall, the effect
of these two drugs appears to be similar [39]. Only one study has
compared the gametocytocidal effect of different artemisinin
derivatives against vivax infection, in a cohort of 284 Indonesian
patients with P. vivax monoinfection or mixed infection [62]. In
total, 56% showed vivax gametocytes on admission. The
prevalence of gametocytemia remained markedly lower with both
AL and DHA-PQP during the 42-d follow-up. After day 14, vivax
gametocytemia seemed to increase among AL-treated patients but
declined again by day 42, while for DHA-PQP-treated patients,
gametocytes did not reappear until day 28 and then began a
modest growth towards the end of follow-up (the gametocyte
carriage rate was 24.6 and 3.7 per 1,000 patient-weeks to day 42
for AL and DHA-PQP, respectively, p,0.001). Assuming that
gametocytes show a similar sensitivity to all artemisinin derivatives,
these findings would be consistent with the hypothesis that the
effect of ACTs on vivax gametocytogenesis is influenced by the
half-life of the partner drug, capable of inhibiting relapses (and
hence new gametocytes) or new infections, but with possibly no
direct effect on existing gametocytes.
To our knowledge, no data are available regarding the specific
impact of AL on the viability of gametocytes, an essential
component for malaria transmission, which is, indeed, more
critical than the absolute presence or absence of gametocytes.
Conclusions
The large burden and wide geographical distribution of P. vivax,
and its clear recognition as a non-benign infection, calls for a
paradigm change in the way we consider this infection. Effective
treatment should be used rationally and rapidly, and although
vivax may still be sensitive in many areas of the world to
chloroquine, we need to acknowledge the new role that
artemisinin derivatives, in combination with primaquine, will
have to play in the short term for its control. AL is now widely
Table 3. Appearance of new P. vivax infections in patients with P. falciparum monoinfection at the time of treatment.
Study Population (Location) Follow-Up Treatment
Sample
Size
New Vivax
Infection p-Value
Hutagulung et al. [58] Adults and children .10 kg (Thailand) 42 d AL 225 40.0% ,0.001
Artesunate-mefloquine 227 12.7%
van den Broek et al. [66] Adults and children $1 y (Bangladesh) 42 d AL 121 20.7% ,0.001
Chloroquine-sulfadoxine-
pyrimethamine
122 3.3%
Artesunate-mefloquine 121 5.0%
Smithuis et al. [64] Adults and children .6m oa n d.5k g
(Myanmar)
63 d AL 137 35.8% ,0.001
Artesunate-amodiaquine 129 29.5% n.s.
Artesunate-mefloquine (fixed dose) 148 31% Reference group
Artesunate-mefloquine (loose tablet) 130 32.3% 0.0001
DHA-PQP 135 34% n.s.
Mayxay et al. [61] Adults and children $1 y (Laos) 42 d AL 110 1.5% n.s.
Chloroquine-sulfadoxine-
pyrimethamine
110 0
Artesunate-mefloquine 110 0
n.s., not significant.
doi:10.1371/journal.pntd.0001325.t003
www.plosntds.org 7 December 2011 | Volume 5 | Issue 12 | e1325deployed for the treatment of falciparum malaria, based on
extensive evidence of consistently high efficacy and an extensive,
convincing safety data base. Clinical trials in vivax malaria are
scarcer. The available data show that AL offers good efficacy
against the blood stages of P. vivax infection, providing rapid
clearance of both parasites [38,56,57] and fever [56,57]. Although
ACTs such as AL, in which the partner drug has a relatively short
half-life, are less vulnerable to emergence of resistant parasites,
they are also associated with a shorter time to vivax recurrence.
This issue could be overcome by co-administration of a full radical
cure using primaquine at its standard dosage [57], although more
trials are required. As with other treatments for vivax malaria,
primaquine therapy should be administered in combination with
AL when used to treat P. vivax infections, preferably after
ascertainment of G6PD status. In areas of high transmission, or
when G6PD deficiency cannot be easily excluded and primaquine
use is erratic, other ACT combinations in which the half-life of the
partner drug is longer (e.g., DHA-PQP) may be more efficacious
to prevent relapses. However, the use of AL remains a valid
alternative, and a pragmatic choice. Finally, AL and other
artemisinin derivatives quickly clear P. vivax gametocytes [71,82],
but the benefit in terms of reducing transmission rate is muted by
the high rate of gametocyte carriage that is typical in vivax
infections [62,71,76].
A unified treatment strategy for the asexual forms of both
falciparum and vivax infections would offer important logistical
advantages. However, the incomplete nature of current data on
the efficacy of AL, and of ACTs in general, in the treatment of P.
vivax monoinfections and/or the prevention of P. vivax relapses or
new infections compels the malaria community to assess urgently
the efficacy, cost-effectiveness, safety, and toxicity of these drugs
on their own and in association with effective antihypnozoite
treatment.
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